Peptide leads new class of chronic pain drugs.
Garber
Ken
K
D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D020864:Calcium Channels, N-Type / Q000187:drug effects*; D002908:Chronic Disease; D006801:Humans; D062559:NAV1.8 Voltage-Gated Sodium Channel; D009475:Neurons, Afferent / Q000187:drug effects; D010146:Pain / Q000188:drug therapy*; D010455:Peptides / Q000627:therapeutic use*; D000069583:Pregabalin; D015222:Sodium Channels / Q000627:therapeutic use; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D020960:omega-Conotoxins / Q000627:therapeutic use
D002121:Calcium Channel Blockers; D020864:Calcium Channels, N-Type; D062559:NAV1.8 Voltage-Gated Sodium Channel; D010455:Peptides; C568317:SCN10A protein, human; D015222:Sodium Channels; D020960:omega-Conotoxins; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid; C078452:ziconotide